NV-PROOVSTATION
9.1.2020 16:34:11 CET | Business Wire | Press release
Plans are being implemented for up to 40 inspection portals to be deployed across the BCA Group, starting in February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200109005586/en/
At the 2020 CES in Las Vegas, ProovStation and BCA Group, Europe’s leading vehicle remarketing company, today confirmed a commercial agreement to implement ProovStation inspection portals in BCA auctions and logistics compounds across Europe. The roll-out, which is planned to cover 13 countries, will commence in February.
Thanks to industry-leading artificial intelligence, ProovStation portals will allow BCA to carry out a fully automated damage inspection, including underneath the vehicle, within 3 seconds. As the car drives through the portal, even millimeter-large scratches can be spotted, increasing precision and cost-efficiency.
“We are proud to have been chosen by BCA Group as their site based volume inspection partner. The trust from Europe’s largest seller of used cars is a strong signal of legitimacy for ProovStation and confirms the value of our solutions for the automotive industry in its widest definition. This first large contract is a motivation booster for our team, and we will continue to work hard at revolutionising the vehicle inspection process. We want to turn ProovStation into the international standard in the inspection process for the main market segments: OEM, dealers, rental and logistics service providers ” says Cédric BERNARD, CEO of ProovStation.
Jean-Roch PIAT, Divisional CEO of BCA Europe added: “As the leading marketplace for used vehicles across Europe, BCA is providing the power of accurate real-time decision intelligence capability that connects every aspect of buying and selling with BCA, Europe’s largest used vehicle marketplace. ProovStation AI-powered inspection technology allows us to further increase the accuracy of the damage recognition, at unprecedented levels of speed and unit cost to benefit our customers .”
ABOUT PROOVSTATION
ProovStation automates and standardizes the global automotive inspection process. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
OFFICIAL COMMERCIAL LAUNCH AT CES 2020
For its second participation at the CES, the ProovStation start-up returns to Las Vegas with a finalised product, the official launch for mass production, and the determination to win more contracts. ProovStation will present its latest portal at Eureka Park booth 50841.
ABOUT BCA
BCA works with OEMs, fleet operators and dealers to provide the backbone of Europe's automotive supply chain, remarketing 1.4 million vehicles annually.
From technical and logistics services for new vehicles, refurbishment, storage and logistics for the growing used sector and the core remarketing and auction operation, BCA offers the economies of scale and diversity of services to meet the needs of an impressive portfolio of customers.
As the automotive industry faces a period of unprecedented change, BCA is uniquely placed to deliver a range of linked services through the combined infrastructure of de-fleet facilities, vehicle logistics and preparation centres and physical, hybrid and digital remarketing channels.
BCA is investing and innovating today to deliver accurate real-time decision intelligence capability that allow its customers to operate seamlessly in both physical and digital markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005586/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom